IGF2BP1 promotes the malignant progression of laryngeal squamous cell carcinoma by activating the EMT pathway through m6A RNA methylation of C-MYC
International Immunopharmacology · 2026-08 · 182 · 116741
DOI: 10.1016/j.intimp.2026.116741 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-08. Verfasst von Ming Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Epithelial-Mesenchymal Transition, Proto-Oncogene Proteins c-myc, Laryngeal Neoplasms. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong, Department of Science and Technology of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
N6-methyladenosine (m6A) RNA-binding protein IGF2BP1 has been shown to play a significant role in cancer cell proliferation, cellular stress response, metastasis, and immune modulation. However, its specific function and regulatory mechanism in laryngeal squamous cell carcinoma (LSCC) have not been fully elucidated. Clinically, IGF2BP1 expression was markedly upregulated in 30 cases of LSCC tissue samples and was correlated with poor patient prognosis. Functionally, loss- and gain-of-function studies demonstrated that IGF2BP1 promoted the proliferation, invasion, and migration of LSCC cells in vitro, while knockdown of IGF2BP1 inhibited tumor growth in vivo. Mechanistically, MeRIP-qPCR, RIP-qPCR, dual-luciferase reporter assay, and actinomycin D treatment revealed that IGF2BP1 targeted the 3'UTR of the C-MYC transcript for m6A modification and enhanced its stability. Furthermore, IGF2BP1 induced epithelial-mesenchymal transition (EMT) through the overexpression of C-MYC. In conclusion, these findings suggest that IGF2BP1-mediated m6A modification of C-MYC promotes LSCC progression via the EMT pathway, providing potential biomarkers and therapeutic targets for LSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China; The 2nd Medical College of Binzhou Medical University, Yantai, Shandong, China.
- Shandong Stem Cell Engineering Technology Research Center, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. Electronic address: xue6er6@163.com.
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China. Electronic address: zhang0hua@163.com.
Förderung
- Key Technology Research and Development Program of Shandong
- Department of Science and Technology of Shandong Province
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yang, M., Zhao, X., Wang, M., Zhang, Z., Sui, J., Qin, H., Liu, X., & Zhang, H. (2026). IGF2BP1 promotes the malignant progression of laryngeal squamous cell carcinoma by activating the EMT pathway through m6A RNA methylation of C-MYC. International Immunopharmacology, 182, 116741. https://doi.org/10.1016/j.intimp.2026.116741
Vancouver
Yang M, Zhao X, Wang M, Zhang Z, Sui J, Qin H, et al. IGF2BP1 promotes the malignant progression of laryngeal squamous cell carcinoma by activating the EMT pathway through m6A RNA methylation of C-MYC. International Immunopharmacology. 2026;182:116741. doi:10.1016/j.intimp.2026.116741
BibTeX
@article{Yang2026,
author = {Yang, Ming and Zhao, Xin and Wang, Maomeng and Zhang, Zile and Sui, Jiaxin and Qin, Hanbin and Liu, Xuexia and Zhang, Hua},
title = {IGF2BP1 promotes the malignant progression of laryngeal squamous cell carcinoma by activating the EMT pathway through m6A RNA methylation of C-MYC},
journal = {International Immunopharmacology},
year = {2026},
volume = {182},
pages = {116741},
doi = {10.1016/j.intimp.2026.116741}
}
EUVIMED